11/30/2022: Bebtelovimab is not currently authorized for emergency use in the U.S. because it is not expected to neutralize Omicron subvariants BQ.1 and BQ.1.1.
Use as investigational drug under national emergency declaration for the treatment for COVID-19 patients who meet the FDA's EUA and Huntsville Hospital's Criteria for Use.
Add Formweb to your mobile device
11/30/2022: Bebtelovimab is not currently authorized for emergency use in the U.S. because it is not expected to neutralize Omicron subvariants BQ.1 and BQ.1.1.
Use as investigational drug under national emergency declaration for the treatment for COVID-19 patients who meet the FDA's EUA and Huntsville Hospital's Criteria for Use.
Reviewed: Feb. 2022 (Betelovimab)
Updated: December 2022